BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28

• 

  Business

  Moderna Projects COVID-19 Vaccine Sales at $19 Billion for 2022

  In Moderna’s fourth-quarter 2021 annual report, the company announced $7.2 billion in fourth-quarter revenues and full-year 2021 revenues of $18.5 billion.

  February 24, 2022

   · 

  3 min read

   · 

  Mark Terry
• 

  Genetown

  Takeda-Backed Biotech Grabs $24 Million for tRNA-Based Therapies

  With two proprietary platforms dedicated to developing tRNA-based therapeutics targeting protein dysfunction, hC Bio aims to develop precision protein editing technology to cure genetic diseases.

  February 24, 2022

   · 

  2 min read

   · 

  Hannah Chudleigh
• 

  Research Roundup: Neurons Key to Parkinson’s ID’ed, New ALS Mechanism Discovered

  There’s always more to learn about Parkinson’s, and researchers discovered a specialized group of neurons associated with the disease.

  February 24, 2022

   · 

  5 min read

   · 

  Mark Terry
• 

  Business

  BioSpace Movers & Shakers, Feb. 25

  Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.

  February 24, 2022

   · 

  7 min read

   · 

  Alex Keown
• 

  Drug Development

  Medicago’s Plant-Based Vaccine Bolstered by GSK Adjuvant Wins First Approval

  Not only is this the first approval for a plant-based vaccine, it’s also the first approval for GSK’s adjuvant.

  February 24, 2022

   · 

  4 min read

   · 

  Alex Keown
• 

  Business

  An Enduring Drug Discovery Partnership Built on Complimentary Qualities

  The arrangement provides the opportunity for LJI faculty and postdocs to make a more immediate impact on drug development while offering a different perspective to KKNA.

  February 24, 2022

   · 

  6 min read

   · 

  Heather McKenzie
• 

  Research Collab Uncovers Underlying Mechanism for ALS and Dementia

  Researchers have unlocked a key mechanism behind the gene encoding protein UNC13A which could provide new treatment options for ALS and FTD.

  February 24, 2022

   · 

  3 min read

   · 

  Hayley Shasteen
• 

  Business

  US-Authorized COVID-19 Vaccines Generate More Than $30 Billion in 2021

  Moderna, Pfizer and BioNTech and Johnson & Johnson earned an approximate combined revenue of $31 billion in 2021, thanks to the success of their mRNA vaccines against COVID-19.

  February 24, 2022

   · 

  2 min read

   · 

  Alex Keown
• 

  BioMidwest

  Gut Health: CRISPR-Based Kill Switch Causes Bacteria to Self-Destruct

  The researchers note that engineered strains of EcN have been used to diagnose and treat bacterial infections, cancers, gastrointestinal bleeding, inflammatory disorders, and obesity.

  February 24, 2022

   · 

  5 min read

   · 

  Abbey Glasure
• 

  Drug Development

  Adagio Names Temp CEO, Outlines Plans for COVID-19 Antibody

  Adagio Therapeutics has appointed current COO David Hering as interim CEO, replacing Tillman Gerngross, Ph.D., who communicated his intention to resign in mid-February.

  February 24, 2022

   · 

  2 min read

   · 

  Vanessa Doctor, RN